The German federal parliament will today deliberate on a cannabis reform bill proposed by the federal government. The proposed legislation, backed by Chancellor Olaf Scholz, represents a important shift in Germany’s approach to cannabis, which is currently illegal for recreational use.
The bill aims to legalize controlled cannabis usage for adults under specific conditions, promoting responsible consumption. It includes provisions for private cultivation, non-commercial community farming, and controlled distribution through cultivation associations. This revised bill, initially introduced in April, adopts a more gradual approach to cannabis legalization following consultations with the European Union.
The driving force behind this proposal is the growing use of illicit cannabis, which poses health risks due to uncertain THC levels and potential contaminants. Under the new regulations, adults would be allowed to possess up to 25 grams of cannabis and grow up to three plants for personal use while maintaining strict safeguards to protect German youths.
Cultivation associations would face strict regulations, limiting them to distributing 25 grams per day or 50 grams per month to their members, with a membership cap of 500 residents in Germany. Young adults aged 18 to 21 would have lower possession limits, with a THC content cap.
To ensure the safety of children and young adults, advertising of cannabis would be prohibited, and an awareness campaign led by the Federal Center for Health Education (BZgA) would work to educate the public about cannabis’s effects and risks.
Obviously, this development is of great interest to both cannabis enthusiasts and startup businesses. It is expected to significantly boost Germany’s already substantial medical cannabis market, projected to reach €7.7 billion by 2028, reports Sifted. Several German weed tech startups, including Cantourage, Sanity Group, Demecan, Bloomwell Group, and Cansativa (backed by Snoop Dogg), have already seen substantial increases in funding since medical marijuana was legalized in 2017.Advertisement
However, not all factions support such a progressive approach. The CDU/CSU, a prominent political group in Germany, opposes cannabis legalization. They argue that the proposed reform could have negative effects, especially on individuals under 25. Despite these reservations, the federal government remains optimistic about the potential benefits of decriminalization, including substantial cost savings resulting from a reduction in cannabis-related prosecutions.
Cannaconvo with Peter Su of Green Check Verified
Cannabis Last Week with Jon Purow interviews Peter Su of Green Check Verified. Peter Su is a Senior Vice President with Green Check Verified, the top cannabis banking compliance software/consultancy in the space. A 20+ year veteran of the banking industry, Peter serves on the Banking & Financial Services committee of the National Cannabis Industry Association. He chairs the Banking and Financial Services Committee for the NYCCIA & HVCIA. He is an official member of the Rolling Stone Cannabis Culture Council. And, he is on the board of the Asian Cannabis Roundtable, serving as treasurer.
MJBizCon Speakers Focus on the Challenges, Provide a Glimmer of Hope
Germany Sets 2024 for Cannabis Legalization, Eases Regulations
New York State Clears Path for Dispensary Openings with Lawsuit Settlement
Minnesota Targets 2025 for Cannabis Market Launch
Fetterman Champions Cannabis Legalization in US Senate
A Turning Point in the Cannabis Industry – Insights from the Benzinga Conference
Ohio Voters Legalize Weed in Defiance of GOP Leaders
Global Cannabis Connect: Ohio Edition – December 5 – Columbus
Seeds in the City: Royal Queen Seeds Opens NYC Store
Gov. DeWine Urges Quick Revisions to Ohio’s New Marijuana Law
How Do Cannabis Pros Balance Work and Life?
Leadership, Empathy, and a Noble Cause
The Global Cannabis Times Interview with Kristi Palmer, Kiva Confections Co-Founder
Investment in the European Cannabis Industry with William Muecke & Daniel Grözinger
The first cannabis flower prescription on the NHS with Mike Roberts